LTIP335A - Vaccine for human immunodeficiency virus - Google Patents

Vaccine for human immunodeficiency virus

Info

Publication number
LTIP335A
LTIP335A LTIP335A LTIP335A LTIP335A LT IP335 A LTIP335 A LT IP335A LT IP335 A LTIP335 A LT IP335A LT IP335 A LTIP335 A LT IP335A LT IP335 A LTIP335 A LT IP335A
Authority
LT
Lithuania
Prior art keywords
vaccine
immunodeficiency virus
human immunodeficiency
human
virus
Prior art date
Application number
LTIP335A
Inventor
Gale E Smith
Franklin Volvovitz
Original Assignee
Microgenesys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Microgenesys Inc filed Critical Microgenesys Inc
Publication of LTIP335A publication Critical patent/LTIP335A/en
Publication of LT3365B publication Critical patent/LT3365B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vectore
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
LTIP335A 1991-06-11 1993-02-11 Vaccine for human immunodeficiency virus LT3365B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US71415291A 1991-06-11 1991-06-11

Publications (2)

Publication Number Publication Date
LTIP335A true LTIP335A (en) 1995-01-31
LT3365B LT3365B (en) 1995-07-25

Family

ID=24868938

Family Applications (1)

Application Number Title Priority Date Filing Date
LTIP335A LT3365B (en) 1991-06-11 1993-02-11 Vaccine for human immunodeficiency virus

Country Status (18)

Country Link
EP (1) EP0542998A1 (en)
JP (1) JPH06501851A (en)
CN (1) CN1068266A (en)
AU (2) AU2193192A (en)
BG (1) BG97519A (en)
CA (1) CA2087732A1 (en)
EE (1) EE9400183A (en)
FI (1) FI930577A (en)
HU (1) HUT68355A (en)
IE (1) IE921875A1 (en)
IL (1) IL102092A (en)
LT (1) LT3365B (en)
MX (1) MX9202781A (en)
PL (1) PL297849A1 (en)
PT (1) PT100584A (en)
SK (1) SK18993A3 (en)
WO (1) WO1992022654A1 (en)
ZA (1) ZA924150B (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE40786E1 (en) * 1984-03-16 2009-06-23 The United States Of America As Represented By The Secretary Of The Army Vaccines against intracellular pathogens using antigens encapsulated within biodegradable-biocompatible microspheres
US6017536A (en) * 1993-06-07 2000-01-25 Trimeris, Inc. Simian immunodeficiency virus peptides with antifusogenic and antiviral activities
US5464933A (en) 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
US6479055B1 (en) 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
WO1995017515A1 (en) * 1993-12-23 1995-06-29 University Technologies International Inc. Methods of expressing proteins in insect cells and methods of killing insects
WO1996040191A1 (en) 1995-06-07 1996-12-19 Trimeris, Inc. The treatment of hiv and other viral infections using combinatory therapy
US6395541B1 (en) 1996-05-23 2002-05-28 The Rockefeller University Methods for the identification of compounds capable of inhibiting HIV-1 viral replication employing murine cell lines expressing human topoisomerase I
US6319504B1 (en) 1996-06-24 2001-11-20 University Of Maryland Biotechnology Institute Treatment and prevention of HIV infection by administration of derivatives of human chorionic gonadotropin
US6077662A (en) * 1996-11-27 2000-06-20 Emory University Virus-like particles, methods and immunogenic compositions
US6214540B1 (en) 1997-03-26 2001-04-10 University Of Maryland Biotechnology Institute Chemokines that inhibit immunodeficiency virus infection and methods based thereon
US6583109B1 (en) 1997-06-24 2003-06-24 Robert C. Gallo Therapeutic polypeptides from β-hCG and derivatives
US6548631B1 (en) 1997-09-16 2003-04-15 BIOMéRIEUX, INC. Macrophage derived chemokine (MDC) as an anti-viral agent for the treatment and prevention of lentivirus infection
US6750008B1 (en) 1999-07-09 2004-06-15 Trimeris, Inc. Methods and compositions for inhibition of membrane fusion-associated events, including HIV transmission
US7994278B1 (en) 1999-08-06 2011-08-09 Nobel Biosciences Llc Biologically active polypeptides derived from a novel early stage pregnancy factor designated maternin (MA)
US6623741B1 (en) 2000-02-29 2003-09-23 Trimeris, Inc. Methods and compositions for inhibition of membrane fusion-associated events including RSV transmission
AUPS065002A0 (en) 2002-02-20 2002-03-14 Immunaid Pty Ltd Strategy for retroviral immunotherapy
US7901690B2 (en) 2002-12-03 2011-03-08 University Of Massachusetts Polyvalent, primary HIV-1 glycoprotein DNA vaccines and vaccination methods
CA2543490A1 (en) 2003-10-24 2005-05-06 Immunaid Pty Ltd Method of analysing immune system cycling to monitor and/or treat diseases by the production of regulator t cells
PA8809601A1 (en) 2007-12-24 2009-07-23 Cipla Ltd ANTI-RETROVIRAL COMBINATION
CA2763373C (en) 2009-05-27 2018-01-09 Immunaid Pty Ltd Methods and systems for determining preferred times for administering therapy to treat diseases
MY166794A (en) 2011-08-19 2018-07-23 Ostrich Pharma Kk Antibody and antibody-containing composition
CN102961760B (en) * 2011-09-01 2017-07-18 常州文松生物技术有限公司 Overlapping peptide is used as reagent and its application for preparing Skin-test and detection specific cellular immunity

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL89118A0 (en) * 1988-02-03 1989-08-15 Microgenesys Inc Vaccine containing polypeptides derived from the envelope gene of human immunodeficiency virus type 1

Also Published As

Publication number Publication date
HUT68355A (en) 1995-06-28
LT3365B (en) 1995-07-25
PT100584A (en) 1993-07-30
EE9400183A (en) 1995-12-15
BG97519A (en) 1994-03-24
PL297849A1 (en) 1994-01-24
FI930577A0 (en) 1993-02-10
FI930577A (en) 1993-03-24
IL102092A (en) 1996-11-14
IL102092A0 (en) 1993-01-14
CN1068266A (en) 1993-01-27
JPH06501851A (en) 1994-03-03
AU4028895A (en) 1996-02-22
CA2087732A1 (en) 1992-12-12
EP0542998A1 (en) 1993-05-26
HU9300686D0 (en) 1993-06-28
ZA924150B (en) 1993-02-24
MX9202781A (en) 1993-04-01
SK18993A3 (en) 1993-10-06
IE921875A1 (en) 1992-12-16
WO1992022654A1 (en) 1992-12-23
AU2193192A (en) 1993-01-12

Similar Documents

Publication Publication Date Title
ZA924150B (en) Vaccine for human immunodeficiency virus
AP9200368A0 (en) Vaccine
CZ197595A3 (en) Vaccine preparations
HUP9601466A2 (en) Adjuvants for viral vaccines
ZA936592B (en) Nutrition for persons infected with human immunodeficiency virus
HUP9601462A2 (en) Adjuvants for viral vaccines
EP0631506A4 (en) Selectively deglycosylated human immunodeficiency virus type 1 envelope vaccines.
AP9100332A0 (en) Vaccines
HU9300010D0 (en) Glycoprotein vaccine named ehv-4
GB9210337D0 (en) Feline leukaemia virus vaccine
EP0868196A4 (en) Synthetic vaccine for protection against human immunodeficiency virus infection
AU2347692A (en) Recombinant viral vaccine
HU9203976D0 (en) Vaccine based on modified herpes virus
ZA935165B (en) Developments relating to human immunodeficiency viruses
GB9109763D0 (en) Herpes virus vaccine
GB9111574D0 (en) Developments relating to human immunodeficiency viruses
GB9020799D0 (en) Viral vaccines
GB9020584D0 (en) Vaccine
IL94510A0 (en) Influenza vaccine
GB8712042D0 (en) Virus & vaccine
GB9114714D0 (en) Herpesvirus vaccine
GB9222156D0 (en) Vaccine
GB9206786D0 (en) Vaccine
GB9206797D0 (en) Vaccine
GB9206789D0 (en) Vaccine

Legal Events

Date Code Title Description
TK9A Rectifications: patents

Free format text: 11. KOMPOZICIJA PAGAL 8 PUNKTA, B E S I S K I R I A N T I TUO, KAD REKOMBINANTINIS BALTYMAS SUDARYTAS IS APYTIKSLIAI 757 GP160 VIENA PO KITOS EINANCIU AMINORUGSCIU IR KURIAME VISISKAI PASALINTA APYTIKSLIAI 40 VIENA PO KITOS EINANCIU GALINIU AMINORUGSCIU., 19950815

MM9A Lapsed patents

Effective date: 19960211